Updates are available Erratum dated 2023-04-05
Click to view Erratum: https://doi.org/10.15252/embr.202357070
-
Authors
Ahmadzadeh, Kourosh https://orcid.org/0000-0003-3155-7509
Pereira, Marie
Vanoppen, Margot
Bernaerts, Eline
Ko, Jeong‐Hun
Mitera, Tania
Maksoudian, Christy https://orcid.org/0000-0001-8852-915X
Manshian, Bella B https://orcid.org/0000-0002-3402-3927
Soenen, Stefaan https://orcid.org/0000-0003-2390-3133
Rose, Carlos D
Williams, Graham R
Bassett, J H Duncan
Matthys, Patrick https://orcid.org/0000-0002-9685-6836
Wouters, Carine https://orcid.org/0000-0002-6426-8845
Behmoaras, Jacques https://orcid.org/0000-0002-5170-2606
-
Funding
Funding for this research was provided by:
Duke NUS block fund (6800112‐00‐00)
Fonds Wetenschappelijk Onderzoek (G0C3420N)
Fonds Wetenschappelijk Onderzoek (1S75320N)
UKRI ¦ Medical Research Council (MR/N01121X/1)
- License Information
-
More Information
Article History
Received: 17 October 2022
Revised: 8 December 2022
Accepted: 9 December 2022
First Online: 4 January 2023
Change Date: 5 April 2023
Change Type: Erratum
Change Details: An Erratum to this paper has been published:
Change Details: https://doi.org/10.15252/embr.202357070
Disclosure and competing interests statement
: C.W. obtained unrestricted grants to KU Leuven from Novartis, Roche, GSK immuno‐inflammation and Pfizer. The remaining authors state they have no competing interests or disclosures.
